Le Lézard
Classified in: Health, Science and technology
Subject: Conference

3-Day Course: Biotechnology for the Non-Biotechnologist (Nice, France - April 10-12, 2019) - ResearchAndMarkets.com


The "Biotechnology for the Non-Biotechnologist" conference has been added to ResearchAndMarkets.com's offering.

Ideal for non-Scientists and Scientists who need to understand the basic theory, principles, techniques, and potential of biotechnology

This intensive three-day course is ideal for non-scientists and scientists needing to understand the basic theory, principles, techniques and potential of biotechnology.

You will gain an overview of how biotech products are being developed and manufactured, and discuss the scientific and regulatory environment. The latest advances in regulation will be covered, including biosimilars and advanced therapies. The course will also discuss the role and importance of patents within biotech, including what actually can be patented.

Why Should You Attend?

Who Should Attend

Agenda

Programme Day one

Introduction to Biotechnology

Introduction to Molecular Biology

Re-Expression of Proteins

Development of Production Organisms

Fermentation Technology and Large Scale Production

General Discussion

End of Day One and Drinks Reception

Programme Day two

Process Optimisation and Scale-Up

Analysis of Biopharmaceuticals

Product Recovery and Purification

Formulation Design of Biopharmaceuticals

Process Economics

General Discussion

Programme Day three

Patenting Biotech Inventions

Patent Workshop

Regulatory Considerations of Biopharmaceuticals

Application of Regulatory Principles

Advances in Regulation: Biosimilars

Advances in Regulation: Advanced Therapies

General Discussion

For more information about this conference visit https://www.researchandmarkets.com/research/df8xlq/3day_course?w=4


These press releases may also interest you

at 06:50
Pfizer Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved BEQVEZtm (fidanacogene elaparvovec-dzkt) for the treatment of adults with moderate to severe hemophilia B who currently use factor IX (FIX) prophylaxis...

at 06:08
The Annual General Meeting of Bioretec Ltd was held on 26 April 2024 in Tampere, Finland. The Annual General Meeting approved the financial statements for the financial year 1 January?31 December 2023 and resolved to discharge the members of the...

at 06:00
IDEAYA Biosciences, Inc. , a precision medicine oncology company committed to the discovery and development of targeted therapeutics, today announced that, on April 25, 2024, the Compensation Committee of IDEAYA's Board of Directors granted...

at 06:00
-- Diluted EPS of $2.16; Adjusted Diluted EPS of $2.26 ---- Increases 2024 Full Year Guidance -- 2024 adjusted diluted EPS of $2.26, up over 7% from $2.11 in the first quarter of 2023.Increases 2024 full year adjusted diluted EPS guidance by $0.10 to...

at 06:00
Avantor, Inc. , a leading global provider of mission-critical products and services to customers in the life sciences and advanced technology industries, today reported financial results for its first...

at 05:12
Swedish Orphan Biovitrum AB (publ) (Sobi®) has established a medium term note programme with a framework amount of SEK 10 billion or the equivalent thereof in EUR (the "MTN Programme"). For this purpose, Sobi has prepared a base prospectus, which...



News published on and distributed by: